Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Naoki Izawa

Showing results (61-70 of 65) with videos related to

Pageof 7
Sort By:
You have reached the last page of results.This site can display upto 65 results.
European Journal of Cancer (Oxford, England : 1990)|March 25, 2026
Randomized phase II study of FOLFIRI plus ramucirumab versus FOLFOXIRI plus ramucirumab as first-line treatment for metastatic colorectal cancer: WJOG9216G (RECAST)Yosuke Kito, Kentaro Yamazaki, Hirokazu Shoji, et al.
British Journal of Cancer|August 2, 2023
Mutational spectrum of TP53 gene correlates with nivolumab treatment efficacy in advanced gastric cancer (TP53MUT study)Koji Ando, Yoshiaki Nakamura, Hiroyuki Kitao, et al.
International Journal of Cancer|July 23, 2025
Ramucirumab-containing chemotherapy for patients with gastrointestinal neuroendocrine carcinoma refractory/intolerant to platinum-based chemotherapy: A multicenter observational retrospective study (WJOG13420G)Yuki Matsubara, Toshiki Masuishi, Waki Hosoda, et al.
British Journal of Cancer|November 17, 2023
Dexamethasone-sparing on days 2-4 with combined palonosetron, neurokinin-1 receptor antagonist, and olanzapine in cisplatin: a randomized phase III trial (SPARED Trial)Hiroko Minatogawa, Naoki Izawa, Kazuhiro Shimomura, et al.
European Journal of Cancer (Oxford, England : 1990)|February 15, 2024
Predictive value of CDC37 gene expression for targeted therapy in metastatic colorectal cancerHiroyuki Arai, Yan Yang, Yasmine Baca, et al.
Pageof 7

Showing results (61-70 of 65) with videos related to

Sort By:
Pageof 7
You have reached the last page of results.This site can display upto 65 results.
European Journal of Cancer (Oxford, England : 1990)|March 25, 2026
Randomized phase II study of FOLFIRI plus ramucirumab versus FOLFOXIRI plus ramucirumab as first-line treatment for metastatic colorectal cancer: WJOG9216G (RECAST)Yosuke Kito, Kentaro Yamazaki, Hirokazu Shoji, et al.
British Journal of Cancer|August 2, 2023
Mutational spectrum of TP53 gene correlates with nivolumab treatment efficacy in advanced gastric cancer (TP53MUT study)Koji Ando, Yoshiaki Nakamura, Hiroyuki Kitao, et al.
International Journal of Cancer|July 23, 2025
Ramucirumab-containing chemotherapy for patients with gastrointestinal neuroendocrine carcinoma refractory/intolerant to platinum-based chemotherapy: A multicenter observational retrospective study (WJOG13420G)Yuki Matsubara, Toshiki Masuishi, Waki Hosoda, et al.
British Journal of Cancer|November 17, 2023
Dexamethasone-sparing on days 2-4 with combined palonosetron, neurokinin-1 receptor antagonist, and olanzapine in cisplatin: a randomized phase III trial (SPARED Trial)Hiroko Minatogawa, Naoki Izawa, Kazuhiro Shimomura, et al.
European Journal of Cancer (Oxford, England : 1990)|February 15, 2024
Predictive value of CDC37 gene expression for targeted therapy in metastatic colorectal cancerHiroyuki Arai, Yan Yang, Yasmine Baca, et al.
Pageof 7